About

>Advisory Board

Advisory Board

Dr. Ramon Diaz-Arrastia

University of Pennsylvania Perelman School of Medicine

Presidential Professor Director of Clinical Traumatic Brain Injury Research
DR. Robert Stern

Boston University School of Medicine

Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology Director of the Clinical Core of the BU Alzheimer’s Disease Center Director of Clinical Research for the BU Chronic Traumatic Encephalopathy (CTE) Center
Dr. Thomas Joos

Natural and Medical Sciences Institute (NMI)

Deputy Managing Director at the University of Tübingen, Co-Founder, Signatope GMBH
Professor Henrik Zetterberg

University of Gothenburg

Professor of Neurochemistry, University of Gothenburg, Sweden, and University College London, UK Head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy at the University of Gothenburg, Sweden
Dr. Jens Kuhle

University Hospital Basel

Head Multiple Sclerosis Centre, Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research
Dr. Andrew Nixon

Member of the Duke Cancer Institute

Associate Professor in Medicine
Dr. Maribeth Raines

President of MBBB Solutions
Professor David Leppert

University of Basel

Department of Neurology, Associate Professor

Dr. Ramon Diaz-Arrastia

University of Pennsylvania Perelman School of Medicine

Presidential Professor Director of Clinical Traumatic Brain Injury Research

Dr. Diaz-Arrastia is Professor of Neurology at the University of Pennsylvania, where he leads the TBI Clinical Research Initiative. His research interests are focused on understanding the molecular, cellular, and tissue level mechanisms of neuronal injury and neuroregeneration, with the goal of developing therapies for neurotrauma. Dr. Diaz-Arrastia received his MD and PhD degrees from Baylor College of Medicine, and completed post-graduate training at Harvard and Columbia. Prior to coming to Penn, he served on the faculty at the University of Texas Southwestern, the Uniformed Services University of the Health Sciences, and the National Institute of Neurologic Disorders and Stroke (NINDS). Dr. Diaz-Arrastia has published over 200 primary research papers, as well as over 40 invited reviews and book chapters. He has also served in several national committees related to brain injury research and practice, convened by the Institute of Medicine, the National Institutes of Health, the Department of Defense, and the Veterans Administration.
DR. Robert Stern

Boston University School of Medicine

Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology Director of the Clinical Core of the BU Alzheimer’s Disease Center Director of Clinical Research for the BU Chronic Traumatic Encephalopathy (CTE) Center

Dr. Robert Stern is Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology at Boston University School of Medicine, where he is also Director of the Clinical Core of the BU Alzheimer’s Disease Center (one of only 29 centers funded by the National Institutes of Health, NIH), and Director of Clinical Research for the BU Chronic Traumatic Encephalopathy (CTE) Center. A major focus of his research involves the long-term effects of repetitive brain trauma in athletes, including the neurodegenerative disease, CTE. He has funding from NIH and the Department of Defense for his work on developing methods of detecting and diagnosing CTE during life, as well as examining potential genetic and other risk factors for this disease. His other major areas of funded research include the assessment and treatment of Alzheimer’s disease, the cognitive effects of chemotherapy in the elderly, thyroid-brain relationships, and driving and dementia. Dr. Stern has also published on various aspects of cognitive assessment and is the senior author of many widely used neuropsychological tests, including the Neuropsychological Assessment Battery (NAB). Dr. Stern has received several NIH and other national grants, has published over 250 journal articles, chapters, and abstracts, and is a Fellow of both the American Neuropsychiatric Association and the National Academy of Neuropsychology. He is on several editorial boards and is on the Medical and Scientific Advisory Boards of the MA/NH Chapter of the Alzheimer’s Association and Sports Legacy Institute, and is also a member of the Mackey-White Traumatic Brain Injury Committee of the NFL Players Association. Dr. Stern has testified before the US Senate Special Committee on Aging. He appears frequently in national and international print and broadcast media for his work on CTE and AD. He also appears in the feature length documentaries, “League of Denial” (PBS Frontline, 2013), “Head Games” (2012), and “I Remember Better When I Paint” (2009).
Dr. Thomas Joos

Natural and Medical Sciences Institute (NMI)

Deputy Managing Director at the University of Tübingen, Co-Founder, Signatope GMBH

Dr. Thomas Joos joined 1998 the NMI at the University of Tuebingen heading the department of biochemistry. Since 2013 he is the deputy managing director of NMI. His research is focused on miniaturized multiplexed immunoassays for biomarker research and diagnostic applications. Dr. Joos studied Biochemistry at the University of Tubingen. He performed his Ph.D. degree in 1995 on integrin‐alpha5 during early embroygenesis of Xenopus laevis in the laboratory of Prof. Peter Hausen at the Max‐Planck‐Institute of Developmental Biology. Dr. Joos is a member of the editorial board of Drug Discovery Today, Proteomics, Molecular Biotechnology and Expert Review of Proteomics. He is a member of the scientific advisory board of the "Plasma Proteome Institute" Washington, DC, USA, and of Myriad‐RBM, Austin, TX, USA. Dr. Joos is co-founder of SIGNATOPE, Reutlingen, Germany, a protein biomarker company offering assay development and screening services for any protein in any species.
Professor Henrik Zetterberg

University of Gothenburg

Professor of Neurochemistry, University of Gothenburg, Sweden, and University College London, UK Head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy at the University of Gothenburg, Sweden

Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London (UCL), UK, and a Clinical Chemist at the Sahlgrenska University Hospital in Gothenburg. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and academic lead of the Dementia Research Institute Fluid Biomarker Laboratory at UCL. His main research focus and clinical interest are fluid biomarkers for CNS disorders.
Dr. Jens Kuhle

University Hospital Basel

Head Multiple Sclerosis Centre, Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research

Dr Jens Kuhle obtained his MD from the Eberhard-Karls University in Tübingen, Germany and specialised in neurology and neuroimmunology at the University Hospital Basel. His research activities focused on biofluid markers related to course and outcome of neurological diseases in general, and specifically on establishing neurofilament light chain as the first blood based biomarker in MS. Based on this research, he received his PhD entitled “Towards quantifying neuronal damage in blood samples from patients with neurological diseases” in Neuroimmunology at Queen Mary University London, UK. He is a Swiss board certified neurologist, and has recently been appointed as Head of the newly founded Multiple Sclerosis Centre at the University Hospital Basel. Further, he is the Principal Investigator of the Swiss MS Cohort Study, a national academic network dedicated on biomarker and outcome research in MS.
Dr. Andrew Nixon

Member of the Duke Cancer Institute

Associate Professor in Medicine

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.
Dr. Maribeth Raines

President of MBBB Solutions

Dr. Maribeth Raines is currently an independent biomarker consultant with a broad-based background in a variety of areas but especially in oncology, inflammation, and virology as well as in biomarker discovery, development, and commercialization. She was previously the Vice President of Laboratory Services at Pacific Biomarkers, a CRO supporting the medical device and pharmaceutical industries. Prior to joining Pacific Biomarkers, Dr. Raines served as Director of Scientific Affairs for Quest Diagnostics Clinical Trials, where she helped establish biomarker, anatomic pathology, and flow cytometry testing for drug development. She was also responsible for building strategic alliances in emerging markets, standardizing processes, and harmonizing test results among multiple laboratories for global biomarker deployment. Prior to that position, she served as Director of R&D; at both Nichols Institute Diagnostics and BioSource International (now known as Life Technologies). In addition, she has served on the faculty at UCLA School of Medicine in the Radiation Oncology Division. Dr. Raines earned a B.S. degree in Biology from St. Francis University, and a Ph.D. in Biochemistry from Michigan State University.
Professor David Leppert

University of Basel

Department of Neurology, Associate Professor

Navigate with arrow keys

>Advisory Board

Advisory Board

Dr. Ramon Diaz-Arrastia

University of Pennsylvania Perelman School of Medicine

DR. Robert Stern

Boston University School of Medicine

Dr. Thomas Joos

Natural and Medical Sciences Institute (NMI)

Professor Henrik Zetterberg

University of Gothenburg

Dr. Jens Kuhle

University Hospital Basel

Dr. Andrew Nixon

Member of the Duke Cancer Institute

Dr. Maribeth Raines

President of MBBB Solutions

Professor David Leppert

University of Basel

Dr. Ramon Diaz-Arrastia

University of Pennsylvania Perelman School of Medicine

Presidential Professor Director of Clinical Traumatic Brain Injury Research

DR. Robert Stern

Boston University School of Medicine

Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology Director of the Clinical Core of the BU Alzheimer’s Disease Center Director of Clinical Research for the BU Chronic Traumatic Encephalopathy (CTE) Center

Dr. Thomas Joos

Natural and Medical Sciences Institute (NMI)

Deputy Managing Director at the University of Tübingen, Co-Founder, Signatope GMBH

Professor Henrik Zetterberg

University of Gothenburg

Professor of Neurochemistry, University of Gothenburg, Sweden, and University College London, UK Head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy at the University of Gothenburg, Sweden

Dr. Jens Kuhle

University Hospital Basel

Head Multiple Sclerosis Centre, Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research

Dr. Andrew Nixon

Member of the Duke Cancer Institute

Associate Professor in Medicine

Dr. Maribeth Raines

President of MBBB Solutions

Professor David Leppert

University of Basel

Department of Neurology, Associate Professor